Compared with individuals in the metformin and second- or third-line glucose-lowering medications groups, major CVEs were significantly lower in individuals with NAFLD and type 2 diabetes who received GLP-1RAs but not different from those who received SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.